Xspray's Q2 report provided some color on the Dasynoc and Nilopki regulatory processes that anchor the case, with Dasynoc's PDUFA date now less than three weeks away. The market was not impressed by the report, sending shares down ~6%, leaving the stock screening as "Attractively priced" compared to Redeye's weighted fair value.
LÄS MER
